Regeneron Pharmaceuticals, Inc. - Common Stock · Transaction May 15, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · REGN
+2.65% · +$19.97 · Vol Not reported
Live · updated 12:06:29 ET
Regeneron Pharmaceuticals Inc
Biotechnology
$773.09
Follow $REGN
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $REGN by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredTue Oct 13 · last completed session · daily score · 19h old · REGN
MethodologyREGN
Regeneron Pharmaceuticals Inc
Tue Oct 13 · last completed session · daily score · 19h old
Highest qualified
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
80/ 100
Veridion Score
Highest qualified · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Tue Oct 13 · last completed session · daily score · 19h old
AI Analysis
SovereignWhy is REGN moving today?
Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Regeneron Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
15K
Country
US
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$758.17
Day high
$774.11
Day low
$755.21
Previous close
$753.12
52W high
$852.03
-9.26% from high
52W low
$569.17
72% of range
Market cap
$77.5B
P/E
18.12×
EPS
$40.45
Beta
0.53
Shares out
103M
Avg volume
706.2K
VWAP
$753.12
Last session
Price history computed in-house
1W
+4.17%
1M
-2.60%
3M
+13.87%
1Y
+35.01%
YTD
+0.16%
SMA 50 $789.57 · below
SMA 200 $735.29 · above
52W position 72%
REGN overview
SEC industry peers
REGN peers
Related filings and maps
Public disclosures
Congress activity in REGN
21 filers · 35 buys · 46 sells (1 labeled S (partial)) · Jan 30, 2014 to May 15, 2026 · House 71 / Senate 10
All available history · Latest 5 of 81 lines · Read Oct 14, 2026, 4:06 PM UTC
Official filing ↗
Regeneron Pharmaceuticals, Inc. - Common Stock · Transaction Nov 18, 2025 · Filed Dec 15, 2025 · $1,001 to $15,000
Regeneron Pharmaceuticals, Inc. - Common Stock · Transaction May 15, 2025 · Filed Jun 9, 2025 · $1,001 to $15,000
Regeneron Pharmaceuticals, Inc. - Common Stock · Transaction Apr 8, 2025 · Filed May 8, 2025 · $1,001 to $15,000
Regeneron Pharmaceuticals, Inc. - Common Stock · Transaction Apr 1, 2025 · Filed May 14, 2025 · $1,001 to $15,000
Federal contracts
REGN contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for REGN in this window.
Lobbying spend
REGN lobbying filings, year to date.
Registered lobbying filings matched to Regeneron Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for REGN in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for REGN.